Showing results (121-130 of 588) with videos related to

Sort By:
Pageof 59
Seminars in Oncology|January 23, 2019
Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysisChiara Ciccarese, Roberto Iacovelli, Emilio Bria, et al.
Expert Review of Anticancer Therapy|December 21, 2017
The development of PARP as a successful target for cancer therapyRoberto Ferrara, Francesca Simionato, Chiara Ciccarese, et al.
Biomed Research International|June 28, 2014
CXC and CC chemokines as angiogenic modulators in nonhaematological tumorsMatteo Santoni, Sergio Bracarda, Massimo Nabissi, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|October 4, 2023
Bronchoscopically-visible massive central airway cancer cavitation is associated with metastatic disease, lack of actionable mutations and poor prognosis: a case seriesDaniele Magnini, Emilio Bria, Alessandra Cancellieri, et al.
Drugs|April 3, 2026
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical RationaleMarzia Del Re, Elvira Inglese, Emilio Bria, et al.
Biomedicines|February 25, 2022
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI ResistanceAnastasios Gkountakos, Giovanni Centonze, Emanuele Vita, et al.
Cancers|November 14, 2019
PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and TargetLisa Salvatore, Maria Alessandra Calegari, Fotios Loupakis, et al.
European Journal of Clinical Nutrition|March 28, 2018
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapyIlaria Trestini, Luisa Carbognin, Isabella Sperduti, et al.
Expert Opinion on Pharmacotherapy|February 14, 2020
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitorsGiovanna Garufi, Antonella Palazzo, Ida Paris, et al.
Cancers|October 30, 2019
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old StoryGeny Piro, Carmine Carbone, Luisa Carbognin, et al.
Pageof 59